Delcath Systems Inc. (NASDAQ: DCTH), which in pre-market trading shot up 48%, closed the trading session up 18% to close at $3.60 after the FDA granted its chemotherapy agent doxorubicin, used primarily for live cancer an orphan drug status. The Orphan Drug Act was created to encourage and promote research for therapies of rare conditions and diseases that affect less than 200,000 a year in the United States.
LiverCancer posts
Feed
America's 10 Highest-Paid CEOs of 2011 (and How They Earned It)
The Richest Woman in the World: How Gina Rinehart Earns her Billions

